

March 1, 1983

Penelope Bowers, M.D.
Boehringer Ingelheim, Ltd.
90 East Ridge
P.O. Box 368
Ridgefield, CT 06877

Dear Penny,

Enclosed are draft copies of the report, "Pharmacology-EEG Analysis of clonidine (Catapres): Comparison with l-Penbutolol (Betapressin)". The report summarizes the experiences in the two studies of Catapres which we have completed in normal male volunteers.

Catapres exhibits central effects at single doses of 0.075 mg which peak at two hours after dosing and are no longer measurable at four hours. The EEG pattern are those of a sedative or hypnotic, and are not consistent with the changes seen with typical antipsychotic, antidepressant (thymoleptic), or anxiolytic psychoactive substances. In these trials, Catapres elicited some lowering of systolic and diastolic blood pressures and a slowing of the heart rate.

These findings suggest that Catapres elicits direct effects in the CNS, in doses which may be clinically relevant.

A summary of the first study was presented at the ACNP session on Catapres organized by Dr. Richard Resnick, and was published in Psychopharmacology Bulletin (17:16-17, 1981). Do you think a more detailed report should be prepared for publication based on these findings?

Thank you for the opportunity to carry out these trials with this interesting and useful medicinal. My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry